SMART-211

N/A

Report date: 2022/05/10 11:43:15

Base Information

Drug NameSMART-211
Drug Alias NameSMART211
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSmart Immune SAS
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer CenterSmart Immune SAS
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A